Test Price
2,800 AED✅ Home Collection Available
SERPINB6 Gene Deafness, Autosomal Recessive Type 91 Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين SERPINB6 للصمم الوراثي الصبغي الجسدي المتنحي النوع 91 في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
دقة تشخيصية 99.9% عبر مختبر حاصل على شهادة الأيزو وسلسلة تبريد معتمدة. خدمة سحب الدم المنزلي للمستشفيات. توجيه طبي ما بعد الفحص عبر الهاتف.
Accuracy Guarantee: 99.9% Diagnostic Sensitivity with ISO‑accredited processing and dual‑read variant validation.
Premium Logistics: Paid hospital‑grade home collection via ISO‑certified cold‑chain transport and VIP mobile phlebotomy, 8 AM–11 PM daily.
Clinical Guidance: Complimentary telephonic post‑test clinical guidance in result interpretation by a DHA‑licensed geneticist.
Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview
This highly sensitive next‑generation sequencing (NGS) assay screens the entire coding region of the SERPINB6 gene to identify pathogenic variants causing autosomal recessive deafness type 91 (DFNB91). The test supports early clinical diagnosis, personalised hearing management, and informed reproductive planning for UAE families.
| Feature | Our Test | Usual Alternative |
|---|---|---|
| Methodology | NGS (full gene sequencing + CNV analysis) | Single‑gene Sanger or limited panel |
| Diagnostic Precision | 99.9% sensitivity; >100x mean coverage | ~95% for targeted regions |
| Turnaround Time | 3–4 weeks | 4–6 weeks |
| Pre‑test Genetic Counselling | Mandatory, included | Often optional |
Clinical Specialists Involved
Consultant Otolaryngologist (ENT)
Evaluates audiological phenotype, co‑morbidities, and determines urgency of genetic diagnosis.
Clinical Geneticist
Interprets NGS variant pathogenicity, calculates recurrence risk, and recommends cascade testing.
Certified Genetic Counsellor
Draws multi‑generation pedigree, ensures informed consent, and supports emotional navigation of results.
Physician Insight & Safety Protocol
From Dr. PRABHAKAR REDDY (DHA License 61713011): “The SERPINB6 test reveals whether a hidden genetic variant explains a patient’s hearing loss. It empowers families to pursue early cochlear intervention and make informed reproductive choices. Always correlate molecular findings with clinical audiometry—a gene change alone does not replace a thorough ear, nose and throat evaluation.”
Medication Warning: Do not discontinue or modify any prescribed medication, including ototoxic drugs or steroids, without explicit consultation with your treating physician. This test does not replace therapeutic management.
Patient Safety – Exclusion Criteria & Red Flags
- Inability to provide informed consent (e.g., severe cognitive impairment) without a legally authorised representative.
- Acute febrile illness or untreated infection that may compromise specimen integrity.
- Known haematological conditions preventing safe venipuncture (e.g., severe coagulopathy) – consider buccal swab or FTA card alternative.
- ER Red Flags: Sudden, rapidly progressive unilateral hearing loss with vertigo requires urgent ENT assessment; do not delay care for genetic testing. Signs of meningitis, head trauma, or acute otitis media must be addressed immediately.
Patient FAQ & Clinical Guidance
1. What is the SERPINB6 gene test and why is it important for hearing loss?
This test sequences the SERPINB6 gene to identify mutations causing autosomal recessive deafness type 91, enabling aetiological confirmation of congenital hearing loss. It helps differentiate genetic deafness from acquired causes, guiding long‑term audiological care, cochlear implant candidacy, and family risk assessment. يُستخدم هذا التحليل لتحديد الطفرات المسببة للصمم الوراثي المتنحي المرتبط بجين SERPINB6، مما يساعد في تأكيد التشخيص وتوجيه خيارات العلاج وإدارة السمع للأسرة.
2. How is the test performed, and what sample is needed?
A small blood sample (5 mL EDTA whole blood) or a painless dried blood spot on an FTA card is collected by a mobile phlebotomist in your home or clinic. Extracted DNA from a prior sample is also accepted. No fasting is required. The specimen is transported under cold‑chain to our ISO‑accredited laboratory, where NGS analysis is completed in 3 to 4 weeks. يتم جمع عينة دم صغيرة (5 مل في أنبوب EDTA) أو بقعة دم جافة على بطاقة FTA في المنزل أو العيادة، وتُحلل خلال 3 إلى 4 أسابيع بتقنية التسلسل الجيني المتقدم.
3. What do the results mean for me and my family?
A positive result confirms the genetic cause of deafness, allowing precise reproductive risk counselling (25% recurrence per pregnancy for autosomal recessive inheritance). It may identify carrier status in siblings and parents, prompting cascade screening. A negative or uncertain result does not exclude all genetic hearing loss; follow‑up with your ENT and geneticist is essential. النتيجة الإيجابية تؤكد السبب الجيني للصمم وتسمح بحساب خطر تكرار الإصابة (25% لكل حمل) وتوجيه الفحوصات العائلية، بينما لا تستبعد النتيجة السلبية الأسباب الوراثية الأخرى.
Pre‑test Information & Collection Logistics
A mandatory genetic counselling session is required to document a detailed family pedigree and obtain written informed consent. Provide the patient’s full clinical history, prior audiograms, and any previous genetic reports. No dietary restrictions or medication adjustments are necessary. Acceptable samples:
- 5 mL whole blood in EDTA tube
- One drop of blood on FTA card (dried blood spot)
- 2 µg of extracted DNA (≥50 ng/µL, purity OD 260/280 1.8–2.0)
Samples are transported via dedicated cold‑chain logistics. Turnaround time: 3–4 weeks from receipt of correct specimen.
UAE Regulatory Compliance: This service strictly adheres to Federal Decree‑Law No. 41 of 2024 (Art. 87) on genetic testing, the Child Data Security Law (CDS 2026) for minors requiring parental/guardian consent, and UAE PDPL for data privacy. Genetic counselling and‑specific informed consent are mandatory. Laboratory operations hold ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139) and are licensed by DHA/MOHAP.
ICD‑10‑CM Codes (2026): H90.3 (Sensorineural hearing loss, bilateral) | Z82.2 (Family history of deafness) | Z14.8 (Genetic carrier for other disease)
LOINC Code: 81225‑8 – SERPINB6 gene [Presence] in Blood by Sequencing (loinc.org/81225-8)
Facility License: 9834453
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians